SAM
RYTM icon

Silvercrest Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Silvercrest Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.08M Buy
46,887
+12,760
+37% +$1.24M 0.03% 453
2025
Q4 		$3.65M Buy
34,127
+43
+0.1% +$4.56K 0.03% 468
2025
Q3 		$3.44M Sell
34,084
-14,691
-30% -$1.36M 0.02% 473
2025
Q2 		$3.08M Buy
+48,775
New +$2.99M 0.02% 491

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Silvercrest Asset Management's RYTM Position: Q1 2026 in Review

Silvercrest Asset Management increased its Rhythm Pharmaceuticals (RYTM) stake by 37% in Q1 2026, buying an estimated $1.24M and bringing the position to 46,887 shares worth $4.08M. The position accounts for 0.03% of the portfolio, ranked #453.

Silvercrest Asset Management first reported a position in RYTM in Q2 2025 and has held it in 4 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Silvercrest Asset Management held 46,887 shares of Rhythm Pharmaceuticals worth $4.08M as of Q1 2026.
  • Silvercrest Asset Management bought 12,760 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $1.24M.
  • Rhythm Pharmaceuticals made up 0.03% of Silvercrest Asset Management's portfolio in Q1 2026, its #453 holding.
  • Silvercrest Asset Management first reported a position in Rhythm Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.